Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Capital Expenditures: 2012-2025

Historic Capital Expenditures for Aytu Biopharma (AYTU) over the last 5 years, with Jun 2025 value amounting to $17,000.

  • Aytu Biopharma's Capital Expenditures fell 94.83% to $17,000 in Q2 2025 from the same period last year, while for Jun 2025 it was $228,000, marking a year-over-year increase of 101.32%. This contributed to the annual value of $228,000 for FY2025, which is 30.70% down from last year.
  • Per Aytu Biopharma's latest filing, its Capital Expenditures stood at $17,000 for Q2 2025, which was down 75.36% from $69,000 recorded in Q1 2025.
  • Over the past 5 years, Aytu Biopharma's Capital Expenditures peaked at $329,000 during Q2 2024, and registered a low of -$13.1 million during Q2 2021.
  • For the 2-year period, Aytu Biopharma's Capital Expenditures averaged around $111,400, with its median value being $69,000 (2025).
  • Data for Aytu Biopharma's Capital Expenditures shows a maximum YoY plummeted of 123.21% (in 2021) over the last 5 years.
  • Quarterly analysis of 3 years shows Aytu Biopharma's Capital Expenditures stood at -$13.1 million in 2021, then reached $6,000 in 2024, then slumped by 94.83% to $17,000 in 2025.
  • Its Capital Expenditures stands at $17,000 for Q2 2025, versus $69,000 for Q1 2025 and $6,000 for Q4 2024.